Literature DB >> 27394062

High-resolution CT findings of primary lung cancer with cavitation: a comparison between adenocarcinoma and squamous cell carcinoma.

Y Kunihiro1, T Kobayashi2, N Tanaka3, T Matsumoto4, M Okada2, M Kamiya2, K Ueda5, H Kawano6, N Matsunaga2.   

Abstract

AIM: To evaluate the high-resolution computed tomography (CT) findings of primary lung cancer with cavitation and compare the findings in adenocarcinoma and squamous cell carcinoma.
MATERIALS AND METHODS: The high-resolution CT findings of tumours with cavitation were retrospectively evaluated in 60 patients. Forty-seven of the lesions were diagnosed as adenocarcinomas; 13 were diagnosed as squamous cell carcinomas. The diameters of the tumour and cavity, the maximum thickness of the cavity wall, shape of the cavity wall, the number of cavities, and the presence of ground-glass opacity, bronchial obstruction, intratumoural bronchiectasis, emphysema, and honeycombing were evaluated. The mechanisms of cavity formation were examined according to the pathological features.
RESULTS: The maximum thickness of the cavity wall was significantly greater in squamous cell carcinomas than in adenocarcinomas (p=0.002). Ground-glass opacity and intratumoural bronchiectasis were significantly more common in adenocarcinomas than in squamous cell carcinomas (p<0.001 and p=0.040, respectively). Regarding the pathological findings, intratumoural bronchiectasis with or without alveolar wall destruction contributed to a significant difference between adenocarcinoma and squamous cell carcinoma (p<0.001; odds ratio [OR], 20.35; 95% confidence interval [CI], 3.87-107.10).
CONCLUSION: The cavity wall tends to be thicker in squamous cell carcinomas than in adenocarcinomas. The presence of ground-glass opacity and intratumoural bronchiectasis is strongly suggestive of adenocarcinoma.
Copyright © 2016 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 27394062     DOI: 10.1016/j.crad.2016.06.110

Source DB:  PubMed          Journal:  Clin Radiol        ISSN: 0009-9260            Impact factor:   2.350


  6 in total

1.  Radiomics for Classifying Histological Subtypes of Lung Cancer Based on Multiphasic Contrast-Enhanced Computed Tomography.

Authors:  Linning E; Lin Lu; Li Li; Hao Yang; Lawrence H Schwartz; Binsheng Zhao
Journal:  J Comput Assist Tomogr       Date:  2019 Mar/Apr       Impact factor: 1.826

2.  Non-invasive classification of non-small cell lung cancer: a comparison between random forest models utilising radiomic and semantic features.

Authors:  Usman Bashir; Bhavin Kawa; Muhammad Siddique; Sze Mun Mak; Arjun Nair; Emma Mclean; Andrea Bille; Vicky Goh; Gary Cook
Journal:  Br J Radiol       Date:  2019-06-05       Impact factor: 3.039

3.  Phosphatidylinositol 3-Kinase/Protein Kinase B/Mammalian Target of the Rapamycin Pathway-Related Protein Expression in Lung Squamous Cell Carcinoma and Its Correlation with Lymph Node Metastasis.

Authors:  Fang Shi; Ling Li
Journal:  J Oncol       Date:  2022-08-23       Impact factor: 4.501

4.  Federated Learning Approach with Pre-Trained Deep Learning Models for COVID-19 Detection from Unsegmented CT images.

Authors:  Lucian Mihai Florescu; Costin Teodor Streba; Mircea-Sebastian Şerbănescu; Mădălin Mămuleanu; Dan Nicolae Florescu; Rossy Vlăduţ Teică; Raluca Elena Nica; Ioana Andreea Gheonea
Journal:  Life (Basel)       Date:  2022-06-26

5.  Clinical and radiological characteristics of central pulmonary adenocarcinoma: a comparison with central squamous cell carcinoma and small cell lung cancer and the impact on treatment response.

Authors:  Zhe Wang; Minghuan Li; Yong Huang; Li Ma; Hui Zhu; Li Kong; Jinming Yu
Journal:  Onco Targets Ther       Date:  2018-05-04       Impact factor: 4.147

6.  The value of bronchial and cavity contraction rates in differentiating benign and malignant pulmonary cavities.

Authors:  Hua Zhang; Xia Qian; Zheng-Hua Liu; Yi Gong
Journal:  BMC Pulm Med       Date:  2020-08-06       Impact factor: 3.317

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.